FDA Purple Book
Licensed biological products, their biosimilars, and when their exclusivity ends. Switch to the table view for every column in a full-screen grid.
Licensed biological products, their biosimilars, and when their exclusivity ends. Switch to the table view for every column in a full-screen grid.
Licensed products
945
across 2,499 presentations
Biosimilars
96
50 interchangeable
Biologic substances
667
71% of licences
Licence holders
286
3.3 licences each
Exclusivity expiring
208
within five years
Source: FDA Purple Book, published monthly · data as of Nov 19, 2026
Licences (BLAs), each counted once. Every BLA is a 351(a) originator or a 351(k) follow-on; a 351(k) licence with any interchangeable presentation counts as interchangeable.
◯ pill: entry▭ box: state◇ diamond: decision⬭ bold: outcome⬭ dashed: left the path
Product presentations (one strength in one container), not licences: CDER (drugs) and CBER (biologics)
| 1,441 | 57.7% | |
| 1,058 | 42.3% |
Product presentations, not licences: one licence can have presentations in several statuses